Dr. Martens plc

BATS-CHIXE:DOCSL Stock Report

Market Cap: UK£713.1m

Dr. Martens Past Earnings Performance

Past criteria checks 2/6

Dr. Martens has been growing earnings at an average annual rate of 2.1%, while the Luxury industry saw earnings growing at 16.7% annually. Revenues have been declining at an average rate of 0.8% per year. Dr. Martens's return on equity is 8.8%, and it has net margins of 3.6%.

Key information

2.1%

Earnings growth rate

2.2%

EPS growth rate

Luxury Industry Growth27.6%
Revenue growth rate-0.8%
Return on equity8.8%
Net Margin3.6%
Next Earnings Update05 Jun 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Dr. Martens makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BATS-CHIXE:DOCSL Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24806293860
30 Jun 24842493820
31 Mar 24877693780
31 Dec 23927863860
30 Sep 239781033950
30 Jun 239891163840
31 Mar 231,0001293730
31 Dec 229791533720
30 Sep 229571773710
30 Jun 229331793430
31 Mar 229081813160
31 Dec 218671183100
30 Sep 21825543040
30 Jun 21799442760
31 Mar 21773352480
31 Dec 20747612190
30 Sep 20722871910
30 Jun 20697812040
31 Mar 20672752170
31 Mar 19454171240
31 Mar 18349-6940
31 Mar 17291-11750
31 Mar 16232-12560
31 Mar 152350500
31 Mar 14164-32240

Quality Earnings: DOCSL has high quality earnings.

Growing Profit Margin: DOCSL's current net profit margins (3.6%) are lower than last year (10.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: DOCSL's earnings have grown by 2.1% per year over the past 5 years.

Accelerating Growth: DOCSL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: DOCSL had negative earnings growth (-71.5%) over the past year, making it difficult to compare to the Luxury industry average (2.4%).

Return on Equity

High ROE: DOCSL's Return on Equity (8.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 16:35
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Dr. Martens plc is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Richard TaylorBarclays
David RouxBofA Global Research
Louise SinglehurstGoldman Sachs